What ICER’s Draft Sickle Cell Disease Report Means for CGT Pricing
Syneos Health experts look at how a recent ICER draft report on Sickle Cell Disease could influence how stakeholders feel about the value of a product prior to approval.
Recently, the Institute for Clinical and Economic Review (ICER) published its draft evidence report for sickle cell disease. The report assesses initial cost-effectiveness thresholds for two potential gene therapies against existing standard of care.
Despite ICER not having authority over the final list prices set by manufacturers, payers increasingly take these assessments into consideration when determining coverage, reimbursement and access. Media often picks up on final ICER assessments, which can influence how stakeholders feel about the value of a product prior to approval. While initial media coverage has been minimal, Endpoints and Fierce Pharma noted that both gene therapies offer promise of a potential cure, adding to pricing speculation in the lead up to price disclosure.
While the final assessment won’t be released until July, ICER’s value assessment of two gene therapy drug candidates for sickle cell disease provides some additional signals about how ICER will value gene therapies going forward. This is significant since we’re on the precipice of a wave of gene therapies entering the market. The science is exciting, but the multimillion-dollar price tags raise questions from health assessors like ICER and payers.
A closer look – What does the ICER report signal for future gene therapies?
The drug pricing watchdog group reaffirmed that an appetite remains for high-priced therapies that demonstrate incredible efficacy. However, there are several notable trends that will be critical for cell and gene therapy manufacturers moving forward:
Manufacturers of cell and gene therapies should pay close attention to the upcoming final report and public meeting scheduled on July 27, 2023, to pick up any additional signals of how their future cell and gene therapies are likely to be assessed.
Are you looking for the expertise and insight needed to guide your organization? Explore what the Syneos Health Reputation & Risk Management team can offer in stakeholder engagement and value communications strategies.